Qualiphi is an upgraded version of the Phi 29 DNA polymerase used in isothermal amplification, which offers improved properties.
Sygnis CEO Pilar de la Huerta said that the need for amplification of nucleic acids from minimal concentrations as present in single cell applications will be a critical issue in the coming era of personalised medicine.
"We expect QUALIPHI to become an essential tool for the DNA amplification needed in these markets," Huerta added.
In 2012, Sygnis granted an exclusive global licence to Qiagen, including sublicensing rights, for the commercialization of Qualiphi in the DNA amplification market.